Liver anticancer potential for BBR is mainly due to the regulation of hepatoma cells via interactions among ESR1, TB52, PTGS2, CCDN1, and MAPK1 pathways, which act on Hub-nodes in those interlinked pathways. Here, ELAVL2 is linked to hepatocellular carcinoma.